The New Horizons in Hemophilia: Preparing for the Advent of Gene Therapy is not to be missed!
Hemophilia A occurs in 1 in 5000 live male births and is caused by a mutation in the gene coding for factor VIII (FVIII), resulting in the loss of functional FVIII protein. Treatment of hemophilia requires lifelong use of clotting factor replacement therapy. Recent clinical trial data and ongoing trials are currently investigating novel therapeutic approaches such as gene therapy to improve management of this condition.
The learning objectives of this program are:
Friday, December 10, 2021
Registration and Dinner: 6:15 PM – 7:00 PM EST
Scientific Session: 7:00 PM – 9:30 PM EST
Hyatt Regency Atlanta
In-person and Live Streaming Satellite Symposium